Innovative Explainable AI Tool Predicts Diseases in Early Stages

Researchers from the University of Utah's Department of Psychiatry and the Huntsman Mental Health Institute have unveiled a groundbreaking open-source software called RiskPath. This innovative toolkit leverages explainable artificial intelligence (XAI) to forecast whether individuals are likely to develop chronic and progressive diseases years before any symptoms manifest. Published in the journal Patterns, the study highlights how RiskPath could revolutionize preventive healthcare by providing highly accurate predictions, ranging from 85% to 99%, based on extensive analysis of health data collected over several years.
Traditional disease prediction systems often fall short in handling long-term health data, typically identifying at-risk individuals correctly only about half to three-quarters of the time. In contrast, RiskPath employs advanced time-series AI algorithms that not only predict disease risk but also explain the contributing factors in an understandable manner for clinicians and patients alike. This transparency helps unravel how different risk factors evolve and influence disease development over time.
The significance of this technology lies in its ability to identify at-risk individuals early, allowing for targeted prevention strategies. Nina de Lacy, MD, MBA, and first author of the study, emphasized the potential impact: by early detection and understanding which risk factors matter most at various life stages, more effective and personalized prevention measures can be implemented. This approach centers on proactive health management rather than reactive treatment.
Validated across three large-scale longitudinal cohorts with thousands of participants, RiskPath has successfully predicted eight different health conditions, including depression, anxiety, ADHD, hypertension, and metabolic syndrome. Notably, researchers discovered that even with just ten key factors—such as screen time and executive function—most conditions could be predicted with high accuracy, simplifying potential clinical adoption.
The system also provides intuitive visualizations that highlight critical periods in a person's life that contribute most to disease risks, thus identifying optimal windows for intervention. The research team is actively exploring integration with clinical decision support tools, preventive health programs, and investigating the neural mechanisms associated with mental illnesses. Future plans include expanding the application to additional diseases and more diverse populations.
This innovative approach signifies a major advancement in predictive medicine, promising more personalized, effective, and preventive healthcare in the near future.
For more information, see the original publication: Nina de Lacy et al, RiskPath: Explainable deep learning for multistep biomedical prediction in longitudinal data, Patterns (2025).
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
States Take Independent Action to Rebuild Public Trust Amid Confusion Over US Vaccine Policies
More states are taking independent steps to restore public trust and coordinate vaccine efforts amidst confusion over federal recommendations, highlighting regional leadership in public health.
FDA Approves Inluriyo for Advanced Breast Cancer Treatment
The FDA has approved Eli Lilly's Inluriyo, an oral treatment for ESR1-mutated advanced breast cancer, offering new hope for patients with treatment-resistant disease after successful clinical trial results.
Financial Challenges for Cancer Survivors Facing High-Cost Immunotherapies, Especially Blood Cancer Patients
New research uncovers the financial hardships faced by cancer survivors, especially those with blood cancers, due to the rising costs of immunotherapy treatments. The study highlights the need for better support systems to ensure treatment accessibility.
Innovative Approach to Studying Mechanical Proteins and Their Role in Muscle Disorders
A groundbreaking technique developed by CNIC researchers enables controlled study of titin's mechanical role in muscle diseases, advancing understanding of muscular disorders and potential therapies.